Yap, TA, Simpkins F, Porte M, Postel-Vinay Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology , Am Soc Clin Oncol Educ Book: 2026
Kim D, Chung H, Abed M, Ma J, Molden N, Shim C, Rajendran D, Yen J, Jeong J, Levy A, Yaniz-Galende E, Blanc-Durand F, Desauw C, Follana P, Bonichon-Lamichhane N, Oudard S, D'Hondt V, Gavoille C, Jandial DD, Meric-Bernstam F, Liu JF, Simpkins F, Randall LM, Leary A, Lackner MR, Harismendy O. Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer , NPJ Precis Oncol
, 30(10): 2026,244
Anna Jo Smith, Caroline Shermoen, Stefanie N Hinkle, Nathanael C Koelper, Lisa Mills, Meredith Doherty, Justin E Bekelman, Fiona Simpkins, Emily M Ko Results of integrating an automated electronic social determinants of health screening survey in a gynecologic oncology practice: a pilot study , Int J Gynecol Cancer
, 36(5): 2026
Jang M, Gysler S, Latif NA, Ko EM, Giuntoli RL 2nd, Kim SH, Simpkins F, Nasioudis D Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies. , Gynecol Oncol Rep: 2025,63:102008. doi: 10.1016/j.gore.2025.102008. eCollection
Jang M, Gysler S, Latif NA, Ko EM, Giuntoli RL 2nd, Kim SH, Simpkins F, Nasioudis D Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies , Gynecol Oncol Rep
. 2025 Dec 16:63:102008, 16(63): 2025
Onecha VV, Suarez-García D, Bosque JJ, Lee H, Simpkins F, Gitto SB, Pryma DA, Bertolet A Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace. , Int J Radiat Oncol Biol Phys: 2025,123(3):656-668. doi: 10.1016/j.ijrobp.2025.05.085
Onecha VV, Suarez-García D, Bosque JJ, Lee H, Simpkins F, Gitto SB, Pryma DA, Bertolet A. Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace , Int J Radiat Oncol Biol Phys. (IF = 6.5): 2025
Smith AJB, Spataro S, Heintz J, Simpkins F, Ko EM Disparities in clinical drug trial participation in endometrial cancer: a real-world analysis. , Am J Obstet Gynecol. (Impact factor 8): 2025
Fiona Simpkins, Alexandra Leary, Lyndsay Willmott, Bradley J. Monk, , Jean-Sébastien Frenel, David C. Starks, Meena Okera, Angeles Alvarez Secord, David M. O’Malley, Lainie Martin, Kaissa Ouali, Martin K. Oehler, Jeffrey C. Goh, Brian M. Slomovitz, Peter C. Lim, Catherine M. Shannon, Robert Neff, Doris Kim, Hailun Li, Danielle Jandial, Floor J. Backes Cyclin E1 is a Predictive Biomarker
of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes From Part 1b of the DENALI Study (GOG-3066)
, Gynecology Oncology; plenary, SGO Annual Meeting, March 2025: 2025
Erin George, Lakeisha Mulugeta-Gordon, Emily M Ko, Sharon Wu, Joanne Xiu, Nathaniel Jones, Premal H Thaker, Thomas J Herzog, Eric J Brown, Dineo Khabele, Fiona Simpkins Impact of CCNE1 Amplification on Molecular Signatures and Patient Outcomes in High Grade Serous Ovarian and Endometrial Cancer , Gynecology Oncology; plenary, SGO Annual Meeting, March 2025: 2025
